Join Lipocine for a virtual R&D investor event featuring key opinion leader (KOL) Dr. Kristina M. Deligiannidis, MD (Zucker Hillside Hospital, Northwell Health, New York), who will join company management to discuss the current treatment landscape and unmet need in postpartum depression (PPD).

PPD is a common and serious mood disorder associated with adverse maternal and infant health outcomes. Effective, fast-acting treatment is critical for the well-being of the family.

The event will highlight Lipocine’s clinical programs with a focus on LPCN 1154 (*BRLIZIO^TM), a bioidentical to naturally occurring neuroactive steroid. LPCN 1154 is being developed with the potential to be the first line option for rapid symptom relief in women with PPD. LPCN 1154 is targeted to have a 48-hour treatment duration in an outpatient setting through a convenient oral form.

The event will provide clinical, regulatory, and development updates, including details on the recently initiated Phase 3 registrational study which is expected to read out in Q2-2026.

A live question and answer session will follow the formal presentations.

*Brand name conditionally approved by the FDA